title: Tocilizumab as an Adjuvant Therapy for Hemophagocytic Lymphohistiocytosis Associated With Visceral Leishmaniasis.
abstract: Leishmaniasis is important as a cause of hemophagocytic lymphohistiocytosis (HLH) and must be considered and excluded in patients with HLH because it can cause severe or even fatal complications. When HLH is present, there is a deficient downregulation of the immune response, leading to an uncontrolled inflammation. We report a case of visceral leishmaniasis-HLH where the therapy with tocilizumab, targeting interleukin 6, help to regulate the immune response for the infection of Leishmania.
authors.affiliation: 1Autoimmune Systemic Diseases Unit, Hospital Clínico San Cecilio, C/Dr Olóriz sn, Granada, Spain; and 2Department of Cellular Biology and Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, P. T. Ciencias de la Salud, Granada, Spain.
authors.forename: Raquel
authors.initials: R
authors.lastname: Rios-Fernández
authors.forename: Jose-Luis
authors.initials: JL
authors.lastname: Callejas-Rubio
authors.forename: Sonia
authors.initials: S
authors.lastname: García-Rodríguez
authors.forename: Jaime
authors.initials: J
authors.lastname: Sancho
authors.forename: Mercedes
authors.initials: M
authors.lastname: Zubiaur
authors.forename: Norberto
authors.initials: N
authors.lastname: Ortego-Centeno
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D051359:Lymphohistiocytosis, Hemophagocytic / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D019947:Receptors, Interleukin-6; C502936:tocilizumab